Treatment possibilities in advanced Parkinson's disease;Kezelési leheto{combining double acute accent}ségek a Parkinson-kór elo{combining double acute accent}rehaladott stádiumában

Ideggyogyaszati Szemle

Volumn 66, Issue 11-12, 2013, Pages 365-371

  Takáts, Annamária ^a   Nagy, Helga ^a   Radics, Péter ^a   Tóth, Adrián ^a   Tamás, Gertrúd ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Advanced and late stage of Parkinson's disease; Indications for advanced therapy; Quality of life

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; ANTIPARKINSON AGENT; APOMORPHINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT;

BRAIN DEPTH STIMULATION; DEMENTIA; DYSKINESIA; FALLING; HOSPITALIZATION; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PHARMACEUTICAL CARE; PSYCHOSIS; QUALITY OF LIFE; REVIEW; AGE; COGNITIVE DEFECT; DRUG TOLERANCE; DUODENUM; GEL; INFUSION PUMP; ORAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; AGE FACTORS; ANTIPARKINSON AGENTS; APOMORPHINE; CARBIDOPA; COGNITION DISORDERS; DEEP BRAIN STIMULATION; DOPAMINE AGENTS; DRUG TOLERANCE; DUODENUM; DYSKINESIA, DRUG-INDUCED; GELS; HUMANS; INFUSION PUMPS, IMPLANTABLE; LEVODOPA; PARKINSON DISEASE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84891945284     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. European Parkinson's Disease Association (EPDA). The European Parkinson's Disease Standard of Care Consensus Statement 2012;Vol II.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76. (Pubitemid 351441488)
3. Braak H, Tredici K, de Vos RA, Jansen-Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. (Pubitemid 36007810)
4. Chaudhuri KR, Healy DG, Schapira A. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45. (Pubitemid 43238347)
5. Barone P, Antonini A, Colosimo C, et al. The Priamo Study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-9.
6. Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol 2012;25:433-47.
7. Fahn S. Is levodopa toxic? Neurology 1996;47:S184-95. (Pubitemid 26422584)
8. Agid Y. Levodopa: is toxicity a myth? Neurology 1998;50:858-63. (Pubitemid 28212806)
9. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord 2004;19:997-1005. (Pubitemid 39302831)
10. Nyholm D. The rationale for continous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism and Rel Disord 2007;13:S13-17. (Pubitemid 47444538)
11. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: Intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63. (Pubitemid 36676295)
12. Cenci A, Ohlin KE, Odin P. Current Options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS & neurological disorders - Drug targets 2011;10:670-84.
13. Fox S, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26:S2-41.
14. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's Disease. Mov Disord 2011;26:S42-80.
15. Oertel WH, Berardell A, Bloem R, et al. Late (complicated) Parkinson's disease. In: Gilhus NE, Barnes M, Brainin M (eds.). European Handbook of Neurological Management. Oxford: Wiley-Blackwell; 2010. pp. 237-67.
16. National Institute of Health and Clinical Excellence. Parkinson's disease: Diagnosis and management in primary and secondary care. 2006. Guideline 35.
17. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-39. (Pubitemid 40862249)
18. Olanow W, Watts RL, Roller W. An algorithm (decision tree) for the management of Parkinson's disease. Neurology 2001;56:S1-88.
19. Miyasaki JM, Martin W, Suchowersky O, Weiner W, Lang AE. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. Neurology 2002;58:11-7.
20. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: Treatment of Parkinson's disease with motor fluctuations and dyskinesia (an evidence-based review). Neurology 2006;66:983-95.
21. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's Disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 2005;20: 190-9. (Pubitemid 40361122)
22. Riedel O. Frequency of dementia, depression and other neuropsychiatric symptoms in 1499 outpatients with Parkinson's disease. J Neurol 2010;257:1073-82.
23. Hoehn MM, Yahr MD. Parkinsonism, onset, progression and mortality. Neurology 1967;17:427-42.
24. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord 2000;15:479-84. (Pubitemid 30333219)
25. Goetz CG, Poewe W, Rascol O et al. Movement Disorders Society Task Force Report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-8. (Pubitemid 39302834)
26. Zhao YJ, Wee HL, Chen YH, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 2010;25:710-6.
27. Coelho M. Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol 2010;257:1524-32.
28. Varanese S, Birnbaum Z, Rossi R, Di Rocco A. Treatment of advanced Parkinson's disease. Parkinsons Dis 2011; 480260. doi: 10.4061/2010/480260.
29. Ossig C, Reichmann H. Treatment of Parkinson's disease in the advanced stage. J Neural Transm 2013;120:523-9.
30. Aschermann Zs, Kovács N, Komoly S: Continuous dopaminergic stimulation in Parkinson's disease: Possibilities in 2013. Ideggyogy Sz 2013;66:209-10.
31. Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegenerative Diseases 2008;5:244-6. (Pubitemid 351347862)
32. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74.
33. Gerschanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. Eur J Neurol 2012;19:1502-8.
34. Foltyne T, Magee C, James C, Webstern GJM, Lees AJ, Limousin P. Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Series. Parkinsons Dis 2013;2013:362908. doi: 10.1155/2013/362908.
35. Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res and Op 2011;27:907-19.
36. Abbruzzese G, Barone P, Bonucelli U, Lopiano L, Antonini A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Functional Neurol 2012;27:147-54.
37. Nyholm D. Duodopa treatment for advanced Parkinson's disease: A review for efficacy and safety. Parkinsonism and Rel Disord 2012;18:916-29.
38. Deuschl G, Schade-Brittinger C, Krack P, et al. A Randomized Trial of Deep - Brain Stimulation for Parkinson's Disease. N Eng J Med 2006;355:896-908. (Pubitemid 44315982)
39. Williams A, Gil SI, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:58191.
40. Tamás G, Takáts A, Radics P, et al. Efficacy of deep brain stimulation in our patients with Parkinson's disease. Ideggyogy Sz 2013;66:115-20.
41. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusions in advanced Parkinson's disease. Parkinsonism and Rel Disord 2009;155:S97-100.
42. Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa and deep brain stimulation in advanced Parkinson's disease. Parkinsonism and Rel Disord 2009;15:728-41.
43. Neville AM, Parsons RW, Askmark H, Nyholm D. Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage. Parkinsonism and Rel Disord 2012;18:686-7.
44. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012;19:1079-85.
45. Johansson A, Nyholm D. Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa-carbidopa intestinal gel in the absence of head-to-head comparisons. Basal Ganglia 2012;2:221-6.
46. Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol 2013;260:2701-14.
47. Antonini A, Odin P, Opiano L, et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 2013;120:1553-8.
48. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 2009;9:859-67.
49. Cenci MA, Ohlin KE, Odin P. Current Options and Future Possibilities for the treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease. CNS and Neurol Disord - Drug Targets 2011;10:670-84.
50. Odin P, Antonini A, Wolters E, Chaudhuri KR. Selecting patients for continuous dopaminergic stimulation therapy. European Neurological Review 2011;6:21-6.
51. Schüpbach M, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's Disease with Early Motor Complications. N Eng J Med 2013;368:620-2.
52. Deuschl G, Schiipbach M, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: Concept and standards of the EARLYSTIM - study. Parkinsonism and Rel Disord 2013;19:56-61.
53. Santos-Gracia D,de la Fuente-Fernández R, Valldeoriola F, et al. Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. J Neurol 2012;259:1668-72.